We are pleased to announce that our portfolio company, GenEditBio, has entered into a strategic partnership with uBriGene Biosciences Inc. This collaboration aims to accelerate the development and global commercialization of GenEditBio’s proprietary Lipid Nanoparticle (LNP) technology for cell and gene therapy applications.

The partnership will leverage GenEditBio’s innovative LNP platform alongside uBriGene’s advanced Contract Research, Development, and Manufacturing Organization (CRDMO) capabilities to advance the clinical application of LNP-based therapies.

**Key Focus Areas of the Collaboration Include:**

- Developing GenEditBio’s novel LNP technology into standardized, high-performance RNA-LNP reagents for broader use in cell and gene therapy.
- Systematically validating the LNP platform across diverse therapeutic scenarios to expand its ex vivo clinical applications.
- Utilizing uBriGene’s regulatory expertise and global network to support regulatory submissions and accelerate commercialization efforts.

GenEditBio is dedicated to creating safe, effective, and accessible in vivo genome editing therapies for genetic diseases with significant unmet needs. This partnership represents a meaningful step toward advancing the research, development, and clinical implementation of LNP technology, with the shared goal of delivering innovative treatments to patients worldwide.